Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2024 | KTd versus KRd followed by maintenance or observation in elderly patients with multiple myeloma

Heinz Ludwig • 23 May 2024
COMy 2024
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide Thalidomide
AGMT MM 02

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, presents findings from a study (NCT02891811) comparing induction therapies carfilzomib, thalidomide, and dexamethasone (KTd) and carfilzomib, lenalidomide, and dexamethasone (KRd) followed by maintenance or observation in elderly patients with multiple myeloma (MM). The study reveals similar efficacy between the two regimens, but KRd is poorly tolerated due to neurocognitive issues. Patients receiving carfilzomib maintenance experience a decreased quality of life (QoL), suggesting it should only be used if there is a significant survival benefit, which was not observed in this population. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Amgen, Takeda, Sanofi
Speaker‘s Bureau, Advisory Boards: Amgen, Takeda, Celgene-BMS, Janssen, Pfizer, Sanofi

More from Heinz Ludwig

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
Heinz Ludwig et al. • 15 Sep 2022
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy 5:06
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy
Heinz Ludwig • 20 Nov 2024
The changing approach to infection management with the influx of novel immunotherapies in myeloma 5:44
The changing approach to infection management with the influx of novel immunotherapies in myeloma
Heinz Ludwig • 20 Nov 2024
The complexities of selecting patients with smoldering myeloma for therapeutic intervention 4:35
The complexities of selecting patients with smoldering myeloma for therapeutic intervention
Heinz Ludwig • 20 Nov 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals